CASE REPORT: NODULAR MELANOMA
Abstract
Nodular melanoma is a rare type of cutaneous melanoma with an increased risk of death. It often mimics benign cutaneous tumors and inflammatory lesions. It has pronounced vertical growth phase and greater thickness at the time of diagnosis which caries ominous prognostic value. Nodular melanoma quickly develops metastases which are often present before the disease is clinically recognised. Here, we report a case of nodular melanoma clinically mimicking seborrheic keratosis. Therapy and 36 months follow-up after primal excision are also presented.
Downloads
References
Kožni rak. Dosegljivo 11.1. 2014 s spletne strani:
http://www.onko-i.si/za_javnost_in_bolnike/vrste_raka/kozni_rak/.
Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, et al. Melanoma M (Zero): Diagnosis and Therapy. ISRN Dermatol. 2013; 2013:616170
Primic Žakelj M, Žagar T, Zadnik V. Epidemiologija malignega melanoma. Radiol Oncol 2007; 41(Suppl 1): S1-12.
Rak v Sloveniji 2010=Cancer in Slovenia. Ljubljana: Onkološki inštitut Ljubljana; 2010. Dosegljivo 11.1.2014 s spletne strani:
http://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/RRS/LP_2010.pdf.
Lallas A, Apalla Z, Chaidemenos G. New Trends in Dermoscopy to Minimize the Risk of Missing Melanoma. J Skin Cancer 2012;2012:820474.
Kelly JW, Chamerlain AJ, Staples MP, et al. Nodular melanoma. No longer as simple as ABC. Aust Fam Physician 2003; 32: 706-9.
Bergenmar M: Nodular histogenetic type -- the most significant factor for thick melanoma: implications for prevention. Melanoma Res 1998; 8: 403-11.
Naldi L, Altieri A, Imberti GL, Gallus S, Bosetti C, La Vecchia C. Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma. An analysis according to different clinico-pathological variants and anatomic locations (Italy). Cancer Causes and Control 2005; 16: 893–99.
Egger ME, Dunki-Jacobs EM, Callender GG, Quillo AR, Scoggins CR, Martin RC 2nd, et al. Outcomes and prognostic factors in nodular melanoma. Surg 2012; Vol 152; 652-60.
Mar V, Roberts H, Wolfe R, English DR, Kelly JW.. Nodular melanoma: A distrinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol 2012; 68: 568-75.
Geller AC, Elwood M, Swetter SM, Brooks DR, Aitken J, Youl PH, et al. Factors Related to the Presentation of Thin and Thick Nodualar Melanoma From a Population – besed Cancer Registry in Queensland Australia. Cancer 2009; 15: 1318-26.
Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, et al. Changes in the Presentation of Nodular and Suerficial Spreading Melanoma Over 35 Years. Cancer 2008; Vol 113; 3341-48.
Izikson L, Sober AJ, Mihm MC Jr, Zembowicz A. Prevalence of Melanoma Clinically Resembling Seborrheic Keratosis. Arch Dermatol 2002; 138:1562-66.
Lin MJ, Mar V, McLean C, Wolfe R, Kelly JW.. Diagnostic accuracy of malignant melanoma according to subtype. Australasian Journal of Dermatology 2014; 55: 35-42
Osnove zdravljenja in spremljanje bolnikov po zaključenem zdravljenju. Dosegljivo 11.1.2014 s spletne strani: http://www.onkoi.si/za_javnost_in_bolnike/vrste_raka/kozni_rak/osnove_zdravljenja_in_spremljanje_bolnikov_po_zakljucenem_zdravljenju/.
Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database of Systematic Reviews Cochrane Database Syst Rev 2013;6:CD008955.
Pretto T, Neri D. Pharmacotherapy for metastatic melanoma: Emerging trends and opportunities for a cure. Pharmacol Ther 2013; 139: 405-11.
Jung GW, Dover DC and Samopek TG. Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009. Br J Dermatol 2014; 170: 136-43.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
